Q-omics provides the consensus-scored C12orf29 profile across patient tissues and cancer cell-line models. C12orf29 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C12orf29 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, C12orf29 RNA expression shows 20,367 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, THCA, and ACC as cancer lineages where C12orf29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C12orf29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C12orf29 survival associations across molecular data types. C12orf29 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C12orf29 RNA expression–survival associations across cancer types. High C12orf29 expression shows unfavorable associations in KIRP, KICH, LUAD, LIHC, UVM and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C12orf29 RNA expression.
This table summarizes C12orf29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C12orf29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C12orf29 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, BLCA, CHOL and LUSC. The THCA box plot shows higher C12orf29 RNA expression in normal versus tumor tissue (log2 FC = −0.497, t-test p < 0.001).
This table shows molecular features associated with C12orf29 in patient tissues and cancer cell lines. In patient samples, C12orf29 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C12orf29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
